David A. Roth - Publications, H-index & Citations

David A. Roth

??? It seems like you gave a single word: "development". Affiliation strings that consist of only "development" don't correspond to a known institution. Could you please provide a complete affiliation string?

55H指数

286论文数

2.7W被引数

收录论文 57

发表时间

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis 系统性红斑狼疮肾炎中生物标志物与贝利木单抗肾脏应答相关性的BLISS-LN III期研究启示

Kidney International

IF12.6

2026-04-27

PREAI

Brad H. Rovin; Richard Furie; Ana Malvar; Cynthia Aranow; Jose M. Pego-Reigosa; Elena Zakharova; Andreas Schwarting; Angela R. Jones-Leone; Paula Curtis; Beulah Ji; David A. Roth; André van Maurik

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS 他米巴罗替与阿扎胞苷联合治疗新诊断高危骨髓增生异常综合征（MDS）的SELECT-MDS-1三期研究的关键结果

Blood Advances

IF7.1

2025-05-09

OAAI

Amy E. DeZern; Sylvain Thepot; Stephane de Botton; Andrea Patriarca; Dries Deeren; Jose-Miguel Torregrossa-Diaz; Giovanni Marconi; Teresa Bernal; Juan Bergua Burgues; Blanca Xicoy; Anna Jonášová; Amer M. Zeidan; Sophie Dimicoli-Salazar; Célestine Simand; David Valcarcel; Maria Diez Campelo; Wanxing Chai-Ho; Lalit Saini; Alice Garnier; Klaus Geissler; Yishai Ofran; Zsolt Nagy; Pramila Krishnamurthy; Michael Lübbert; Grzegorz Basak; Hetty E. Carraway; David A. Sallman; Uma Borate; Valeria Santini; Victoria Campbell; Pierre Fenaux; Thorsten Braun; Francesco Lanza; Jan Maciej Zaucha; David A. Roth; Sofia Paul; Pourab Roy; Michael J. Kelly; Angela Volkert; Jaime Chisholm; Tanya Abdul Malak; Virginia M. Klimek; Thomas Cluzeau

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

BLOOD ADVANCES

IF7.1

2023-04-28

OAAI

de Botton, Stephane; Cluzeau, Thomas; Vigil, Carlos; Cook, Rachel J.; Rousselot, Philippe; Rizzieri, David A.; Liesveld, Jane L.; Fenaux, Pierre; Braun, Thorsten; Banos, Anne; Jurcic, Joseph G.; Sekeres, Mikkael A.; Savona, Michael R.; Roboz, Gail J.; Bixby, Dale; Madigan, Kate; Volkert, Angela; Stephens, Kristin; Kang-Fortner, Qing; Baker, Kristen; Paul, Sofia; McKeown, Michael; Carulli, John; Eaton, Matthew; Hodgson, Graeme; Fiore, Christopher; Kelly, Michael J.; Roth, David A.; Stein, Eytan M.

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data belimumab在老年SLE患者中的安全性和有效性: 临床试验数据的综合分析结果

LUPUS SCIENCE & MEDICINE

IF3.5

2023-03-24

OAAI

D'Cruz, David; Eriksson, Gina; Green, Yulia; Hammer, Anne; Ji, Beulah; Meizlik, Paige; Roth, David A.

Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population

AMERICAN JOURNAL OF KIDNEY DISEASES

IF8.2

2023-03-01

OAAI

Yu, Xueqing; Chen, Nan; Xue, Jun; Mok, Chi Chiu; Bae, Sang-Cheol; Peng, Xiaomei; Chen, Wei; Ren, Hong; Li, Xiao; Noppakun, Kajohnsak; Gilbride, Jennifer A.; Green, Yulia; Ji, Beulah; Liu, Chang; Madan, Anuradha; Okily, Mohamed; Tang, Chun-Hang; Roth, David A.

A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome 序贯贝利木单抗和利妥昔单抗治疗原发性干燥综合征的随机II期研究

JCI INSIGHT

IF6.1

2022-12-08

OAAI

Mariette, Xavier; Barone, Francesca; Baldini, Chiara; Bootsma, Hendrika; Clark, Kenneth L.; De Vita, Salvatore; Gardner, David H.; Henderson, Robert B.; Herdman, Michael; Lerang, Karoline; Mistry, Prafull; Punwaney, Raj; Seror, Raphaele; Stone, John; Daele, Paul La van; van Maurik, Andre; Wisniacki, Nicolas; Roth, David A.; Tak, Paul Peter

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis Open-Label Extension of BLISS-LN Study BLISS-LN研究的开放性扩展

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF7.1

2022-11-01

OAAI

Furie, Richard; Rovin, Brad H.; Houssiau, Frederic; Contreras, Gabriel; Teng, Y. K. Onno; Curtis, Paula; Green, Yulia; Okily, Mohamed; Madan, Anuradha; Roth, David A.

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort

LUPUS SCIENCE & MEDICINE

IF3.5

2022-08-29

OAAI

Blenkinsopp, Selin Cooper; Fu, Qinggong; Green, Yulia; Madan, Anuradha; Juliao, Patricia; Goldman, Daniel W.; Roth, David A.; Petri, Michelle A.

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus 贝利木单抗对系统性红斑狼疮器官损害的影响

ARTHRITIS CARE & RESEARCH

IF3.3

2022-08-04

OAAI

Urowitz, Murray B.; Aranow, Cynthia; Asukai, Yumi; Bass, Damon L.; Bruce, Ian N.; Chauhan, Deven; Dall'Era, Maria; Furie, Richard; Fox, Norma Lynn; Gilbride, Jennifer A.; Hammer, Anne; Ginzler, Ellen M.; Gonzalez-Rivera, Tania; Levy, Roger A.; Merrill, Joan T.; Quasny, Holly; Roth, David A.; Stohl, William; van Vollenhoven, Ronald; Wallace, Daniel J.; Petri, Michelle

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE 长期贝利木单抗治疗SLE患者循环b细胞亚群和免疫球蛋白G水平的降低

LUPUS SCIENCE & MEDICINE

IF3.5

2022-02-07

OAAI

Struemper, Herbert; Kurtinecz, Milena; Edwards, Lisa; Freimuth, William W.; Roth, David A.; Stohl, William

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis 贝利木单抗国际研究狼疮性肾炎试验的二次分析检查了贝利木单抗对狼疮性肾炎患者肾脏结局和肾功能的保护作用

KIDNEY INTERNATIONAL

IF12.6

2022-02-01

100

OAAI

Rovin, Brad H.; Furie, Richard; Teng, Y. K. Onno; Contreras, Gabriel; Malvar, Ana; Yu, Xueqing; Ji, Beulah; Green, Yulia; Gonzalez-Rivera, Tania; Bass, Damon; Gilbride, Jennifer; Tang, Chun-Hang; Roth, David A.

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

ARTHRITIS & RHEUMATOLOGY

IF10.9

2021-12-09

OAAI

Ginzler, Ellen; Guedes Barbosa, Luiz Sergio; D'Cruz, David; Furie, Richard; Maksimowicz-McKinnon, Kathleen; Oates, James; Santiago, Mittermayer Barreto; Saxena, Amit; Sheikh, Saira; Bass, Damon L.; Burriss, Susan W.; Gilbride, Jennifer A.; Groark, James G.; Miller, Michelle; Pierce, Amy; Roth, David A.; Ji, Beulah

Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Sharma, M.; Bashir, B.; Hamilton, E.; Juric, D.; Papadopoulos, K.; Richardson, D.; Shapiro, G.; Hodgson, G.; Ke, N.; D'Ippolito, A.; Henry, S.; Zhu, L.; Rosario, M.; Jolin, H.; Roth, D.; Klimek, V.; Madigan, C.; Kelly, M.

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

LUPUS SCIENCE & MEDICINE

IF3.5

2021-02-10

OAAI

Maslen, Toni; Bruce, Ian N.; D'Cruz, David; Ianosev, Mihaela; Bass, Damon L.; Wilkinson, Christel; Roth, David A.

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

LANCET RHEUMATOLOGY

IF16.4

2021-02-01

PREAI

Sheikh, Saira Z.; Scheinberg, Morton A.; Wei, James Cheng-Chung; Tegzova, Dana; Stohl, William; Toledo, Ricardo Acayaba de; Mucenic, Tamara; Banfi, Mauricio R. Abello; Kathleen, Maksimowicz-McKinnon; Abud-Mendoza, Carlos; Navarra, Sandra; Garcia, Mercedes; Torre, Ignacio Garcia-De La; Ros, Josep Ordi; Levy, Roger A.; Bass, Damon L.; Terres, Jorge Ross; Punwaney, Raj; Harris, Julia; Nami, Alireza; Pierce, Amy; Thorneloe, Kevin S.; Ji, Beulah; Roth, David A.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis 贝利木单抗治疗狼疮性肾炎的两年随机对照试验

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2020-09-17

575

OAAI

Furie, Richard; Rovin, Brad H.; Houssiau, Frederic; Malvar, Ana; Teng, Y. K. Onno; Contreras, Gabriel; Amoura, Zahir; Yu, Xueqing; Mok, Chi-Chiu; Santiago, Mittermayer B.; Saxena, Amit; Green, Yulia; Ji, Beulah; Kleoudis, Christi; Burriss, Susan W.; Barnett, Carly; Roth, David A.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

ARTHRITIS & RHEUMATOLOGY

IF10.9

2019-06-05

OAAI

Wallace, Daniel J.; Ginzler, Ellen M.; Merrill, Joan T.; Furie, Richard A.; Stohl, William; Chatham, W. Winn; Weinstein, Arthur; McKay, James D.; McCune, W. Joseph; Petri, Michelle; Fettiplace, James; Roth, David A.; Ji, Beulah; Heath, Amy

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study

ARTHRITIS & RHEUMATOLOGY

IF10.9

2019-04-16

OAAI

Jayne, David; Blockmans, Daniel; Luqmani, Raashid; Moiseev, Sergey; Ji, Beulah; Green, Yulia; Hall, Leanne; Roth, David; Henderson, Robert B.; Merkel, Peter A.

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

ARTHRITIS & RHEUMATOLOGY

IF10.9

2018-06-15

OAAI

Doria, A.; Stohl, W.; Schwarting, A.; Okada, M.; Scheinberg, M.; van Vollenhoven, R.; Hammer, A. E.; Groark, J.; Bass, D.; Fox, N. L.; Roth, D.; Gordon, D.

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States

ARTHRITIS & RHEUMATOLOGY

IF10.9

2018-04-25

OAAI

Furie, Richard A.; Wallace, Daniel J.; Aranow, Cynthia; Fettiplace, James; Wilson, Barbara; Mistry, Prafull; Roth, David A.; Gordon, David

研究方向